SCHEMBL17017

SCHEMBL17017

CCCCOC(=O)N1CCNCC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.63
SMN1; SMN2 Q16637 2/20 0.63
LMNA P02545 1/20 0.63
ALDH1A1 P00352 3/20 0.44
HRH2 P25021 3/20 0.43
HRH1 P35367 3/20 0.43
ATM Q13315 1/20 0.41
GNAI3 P08754 4/20 0.41
GNAO1 P09471 4/20 0.41
GNAI1 P63096 4/20 0.41
TSHR P16473 2/20 0.41
SIGMAR1 Q99720 1/20 0.40
HTT P42858 1/20 0.40
GBA2 Q9HCG7 1/20 0.39
HPGD P15428 1/20 0.39
KDM4E B2RXH2 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5820669 1.00 POLB (0.63) POLBSMN1; SMN2LMNAALDH1A1HRH2
SCHEMBL18760256 1.00 POLB (0.63) POLBSMN1; SMN2LMNAALDH1A1HRH2
Hydrochloric Acid SCHEMBL1111003 0.98 POLB (0.61) POLBSMN1; SMN2LMNAALDH1A1HRH2
Potassium SCHEMBL30906131 0.98 POLB (0.61) POLBSMN1; SMN2LMNAALDH1A1HRH2
SCHEMBL4082478 0.98 POLB (0.61) POLBSMN1; SMN2LMNAALDH1A1HRH2
SCHEMBL5667296 0.95 LMNA (0.57) POLBSMN1; SMN2LMNAHRH2HRH1
SCHEMBL112600 0.94 SMN1; SMN2 (0.56) POLBSMN1; SMN2LMNAALDH1A1HRH2
SCHEMBL25424462 0.93 LMNA (0.55) POLBSMN1; SMN2LMNAGNAI3GNAO1
SCHEMBL27694189 0.93 LMNA (0.55) POLBSMN1; SMN2LMNAGNAI3GNAO1
SCHEMBL9123475 0.93 LMNA (0.55) POLBSMN1; SMN2LMNAGNAI3GNAO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 542 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116606292-A Pyrido [1,2-a ] pyrimidinone derivatives containing sulfonamide unit, preparation method and application thereof 贵州大学 2023-08-18 CN claimed
CN-109715639-A Crystal form 爱杜西亚药品有限公司 2019-05-03 CN claimed
CN-108586466-A A kind of benzene phenodiazine * class HDM2 inhibitor and its preparation method and application 中国药科大学 2018-09-28 CN claimed
CN-104529942-B A kind of synthetic method of Vanoxerine 天津孚音生物科技发展有限公司 2018-05-15 CN claimed
CN-104529942-A Synthetic method for vanoxerine TIANJIN FUYIN PHARMACEUTICAL INNOVATION CO LTD 2015-04-22 CN claimed
EP-1989185-A1 THERAPEUTIC COMPOUNDS Helicon Therapeutics, Inc. (US) 2008-11-12 EP claimed
WO-2007100851-A1 THERAPEUTIC COMPOUNDS HELICON THERAPEUTICS, INC. (US) 2007-09-07 WO claimed
WO-2006137658-A1 NEW SUBSTITUTED 1,3-THIAZOLE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVING IMMUNOSUPPRESSION AND INFLAMMATION INHIBITORY ACITIVITY, INTERMEDIATE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, A PROCESS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DONGBU HITEK CO., LTD. (KR) 2006-12-28 WO claimed
CN-1165539-C Oxazinocarbazoles for the treatment of CNS diseases �������Ŷ���Լ��������˾ 2004-09-08 CN claimed
CN-1361781-A Oxazinocarbazoles for the treatment of CNS diseases UPJOHN CO (US) 2002-07-31 CN claimed
EP-4747245-A1 PHARMACEUTICAL COMPOUNDS Almac Discovery Limited (GB) 2026-05-27 EP disclosed
EP-4743446-A1 NITRO-CONTAINING COMPOUNDS THAT KILL MYCOBACTERIA Board of Trustees of Michigan State University (US) 2026-05-20 EP disclosed
US-20260078219-A1 Polymer Nanoaggregate Pharmaceutical Composition and Use Thereof ANP TECHNOLOGIES, INC. (US) 2026-03-19 US disclosed
US-12544342-B2 Pharmaceutical composition containing taxane nanoaggregates and use thereof FULGENT GENETICS, INC. (US) 2026-02-10 US disclosed
WO-2025236100-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2025-11-20 WO disclosed
CN-1062904-A ANTIPROLIFERATIVE SUBSTITUTED NAPHTHALENE COMPOUNDS AGOURON PHARMA (US) 1992-07-22 CN disclosed
EP-0276057-A2 Piperazinylpyrimidines as beta-adrenergic receptor blocking agents MERCK & CO. INC. (US) 1988-07-27 EP disclosed
US-4610984-A CEREBRAL INSUFFICIENCY CASSELLA AKTIENGESELLSCHAFT (DE) 1986-09-09 US disclosed
EP-0123977-A1 Substituted piperazin-1-yl-acetic-acid amides, process for their preparation and their use CASSELLA Aktiengesellschaft (DE) 1984-11-07 EP disclosed
US-3933802-A New sulphamoylbenzoic acid amides CIBA-GEIGY CORPORATION (US) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078219-A1 Polymer Nanoaggregate Pharmaceutical Composition and Use Thereof HAO2, HRH1, PHB1 POLB 282/4885SMN1; SMN2 2178/4885LMNA 1643/4885
US-12544342-B2 Pharmaceutical composition containing taxane nanoaggregates and use thereof VHL, LPXN, PLEC POLB 378/4885SMN1; SMN2 312/4885LMNA 1557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.